Efficacy and safety of the regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in the treatment of inflammatory skin diseases including atopic dermatitis
Jonathan Zalevsky(Nektar Therapeutics (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Jonathan I. Silverberg(George Washington University), Stephen M. Schleicher(Tennessee Oncology), Thomas Bieber(CK-CARE), Raj Chovatiya(Rosalind Franklin University of Medicine and Science), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Ajay Nirula(Norwegian Womens Public Health Association), Mary Tagliaferri(Nektar Therapeutics (United States)), Lisa A. Beck(University of Rochester Medicine), Christie Fanton(Nektar Therapeutics (United States)), Danni Yu(National Heart Lung and Blood Institute), Takahiro Miyazaki(Kyushu University), Carsten Schmitz(Beth Israel Deaconess Medical Center), Yi Liu(Nektar Therapeutics (United States)), Melinda Gooderham(Queen's University), Joshua Levy(Centre National de la Recherche Scientifique), David Rosmarin(Indiana University School of Medicine)
Cited by 0
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k